Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Major Depressive Disorder Patients Emphasize Long-Term Nature Of Disease In Feedback Meeting

Executive Summary

Externally hosted patient focused drug development meeting in MDD brings timely messages to US FDA during period of active regulatory review of new applications. Patients stress need for fewer side effects to encourage long-term medication use, and also want fast-acting meds that can “jump start” lifestyle changes. 

You may also be interested in...



Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?

By reducing regulatory uncertainty, US FDA’s Breakthrough Therapy Designation is helping adventurous sponsors try new trial designs and new mechanism in the long-stagnant field of psychiatry drug development. 

Advanced Manufacturing May Require US FDA To Think Differently About Guidance

National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’

Advanced Manufacturing May Require US FDA To Think Differently About Guidance

National Academies report argues that technologies cannot only be evaluated in the context of specific products, and FDA guidance should become both ‘more fluid and targeted.’

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS124402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel